Advertisement

Topics

CSPC nabs China rights to Junshi's anti-PD-1 mAb

05:50 EDT 12 Jul 2018 | SmartBrief

CSPC Pharmaceutical was granted exclusive rights to manufacture and market in China and Taiwan, Shanghai Junshi Biosciences'  -More

Original Article: CSPC nabs China rights to Junshi's anti-PD-1 mAb

NEXT ARTICLE

More From BioPortfolio on "CSPC nabs China rights to Junshi's anti-PD-1 mAb"

Advertisement
Quick Search
Advertisement
Advertisement